Search
Olipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145] … [A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022.
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalInavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers. … _PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation.
Synonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigationalthe administration of naxitamab therapy markedly simpler than that of its predecessor. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigational[A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. … binding at the ATP domain of the epidermal growth factor receptor family kinase domains.
Sotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons. … Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type
Categories: Drugs Used in DiabetesAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib was granted FDA approval on 24 May 2019. … [L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384]
Fimasartan
go.drugbank.com/drugs/DB09279InvestigationalFimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. … It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.
Mixtures: DI-ARAHKOR, ARAHKOR DUOCategories: Agents Acting on the Renin-Angiotensin SystemOmega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawn[A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386] … The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalA novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track … Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer. … [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623]